According to Reuters, Akorn (AKRX) approached by Fresenius (FREG.DE)

German healthcare group Fresenius SE & Co KGaA (FREG.DE) said on Friday that it was in talks with the generic drugmaker Akorn Inc (AKRX) for a potential takeover.

April 25, 2017: German healthcare group Fresenius SE & Co KGaA (FREG.DE) has stepped up its dealmaking, agreeing to buy U.S. generic drugmaker Akorn Inc (AKRX) for $4.75 billion (4.37 billion euros) and the biosimilars arm of Germany’s Merck KGaA.